Skip to main content

Carcinoid Syndrome

6
Pipeline Programs
4
Companies
11
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 10 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Lexicon Pharmaceuticals
Lexicon PharmaceuticalsNJ - Bridgewater
6 programs
1
2
3
Telotristat etipratePhase 31 trial
Telotristat etipratePhase 31 trial
Telotristat etipratePhase 31 trial
Telotristat etipratePhase 21 trial
Telotristat etipratePhase 21 trial
+1 more programs
Active Trials
NCT01932528Completed8
NCT01104415Completed15Est. Feb 2014
NCT00853047Completed23Est. Jun 2014
+3 more trials
Ipsen
IpsenChina - Tianjin
2 programs
BIM 23A760PHASE_21 trial
LanreotidePHASE_3Peptide1 trial
Active Trials
NCT01018953Terminated8Est. Jan 2011
NCT00774930Completed115Est. Dec 2015
Crinetics Pharmaceuticals
2 programs
Randomized: 40 mg PaltusotinePHASE_21 trial
PaltusotinePHASE_31 trial
Active Trials
NCT05361668Completed36Est. Feb 2026
NCT07087054Recruiting141Est. Jan 2030
TerSera Therapeutics
TerSera TherapeuticsIL - Deerfield
1 program
XermeloN/A1 trial
Active Trials
NCT03223428Completed223Est. Jan 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Crinetics PharmaceuticalsPaltusotine
Lexicon PharmaceuticalsTelotristat etiprate
Lexicon PharmaceuticalsTelotristat etiprate
Lexicon PharmaceuticalsTelotristat etiprate
IpsenLanreotide
Crinetics PharmaceuticalsRandomized: 40 mg Paltusotine
Lexicon PharmaceuticalsTelotristat etiprate
IpsenBIM 23A760
Lexicon PharmaceuticalsTelotristat etiprate
Lexicon Pharmaceuticals500 mg [14C]-LX1606
TerSera TherapeuticsXermelo

Clinical Trials (11)

Total enrollment: 904 patients across 11 trials

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

Start: Nov 2025Est. completion: Jan 2030141 patients
Phase 3Recruiting

Telotristat Etiprate for Carcinoid Syndrome Therapy

Start: Mar 2014Est. completion: Mar 201676 patients
Phase 3Completed

Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms

Start: Jan 2014Est. completion: Sep 2018124 patients
Phase 3Completed

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

Start: Jan 2013Est. completion: Mar 2016135 patients
Phase 3Completed

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

Start: May 2009Est. completion: Dec 2015115 patients
Phase 3Completed
NCT05361668Crinetics PharmaceuticalsRandomized: 40 mg Paltusotine

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Start: Apr 2022Est. completion: Feb 202636 patients
Phase 2Completed

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

Start: Jun 2010Est. completion: Feb 201415 patients
Phase 2Completed

Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome

Start: Feb 2010Est. completion: Jan 20118 patients
Phase 2Terminated

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Start: Mar 2009Est. completion: Jun 201423 patients
Phase 2Completed

An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males

Start: Aug 20138 patients
Phase 1Completed

Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO

Start: Jun 2017Est. completion: Jan 2022223 patients
N/ACompleted

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 904 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.